Abstract:BACKGROUND:The immune status in the tumor micro-environment of lung cancer is highly informative, and expression status of some biomarkers in the tumor micro-environment may have deep connected statistical characteristics which could indicate immune status and predict related clinical outcomes. In this study, a panel of 9 immune biomarkers are selected for their possible predictive value of clinical outcomes in early-stage resectable non-small cell lung cancer (NSCLC).METHODS:We introduced a new way of interpreting the expression of Immunohistochemistry-based biomarkers in predicting the prognosis of patients. Immunohistochemistry were performed on surgical samples from 139 patients with NSCLC. Cox regression and subgroup analysis were conducted for the screening of biomarkers that were significant in survival and prognosis. Afterwards, Principle Component Analysis was conducted on screened biomarkers in order to extract characteristic root, which were utilized by an Artificial Neuron Network (ANN) for the prediction of clinical outcomes.RESULTS:Six out of 9 biomarkers were considered significant and were selected for the data analysis. The KMO-Bartlett's Sphericity test was valid (0.658>0.5, P=0.0001). The principle component regression results indicated that the survival was associated with the principle component Z4 (Y=0.316×Z4+2.298, R=0.189, P=0.026). Also, regression-free survival was associated with the principle component Z4 and Z2 (Y=0.314×Z4+0.255×Z2+2.061, R=0.249, P=0.013). Principle components ranking (PCrank) was calculated and after the determination of a cutoff of 0.2, the intergroup comparison of subgrouphigh (PCrank value above 0.2) and subgrouplow (PCrank value below 0.2) was significant in overall survival (OS) (P=0.025). A database search validated our results. Afterwards, the ANN model successfully predicted the clinical outcome, with accuracies of 94.1% and 96.2% respectively in models 1 and 2.CONCLUSIONS:The selected immunological panels have promising potential for predicting the prognosis of resectable NSCLC.

Circulating Anti‐p16a IgG Autoantibodies As a Potential Prognostic Biomarker for Non‐small Cell Lung Cancer

Autoantibodies Against P16 Protein-Derived Peptides May Be a Potential Biomarker for Non-Small Cell Lung Cancer.

Anti-p16 Autoantibodies May Be a Useful Biomarker for Early Diagnosis of Esophageal Cancer

Circulating Antibodies to P16 Protein-Derived Peptides in Breast Cancer

Detecting of P16 Autoantibody As a Potential Early Diagnostic Serum Biomarker in Patients with Cervical Cancer.

B-360 Usefulness of the Ratios of CYFRA21-1 and P53 Autoantibody Immune Complexes to Their Free Antigens in Lung Cancer

Increased Levels of Circulating Anti-ANXA1 IgG Antibody in Patients with Non-Small Cell Lung Cancer.

Peripheral Blood Autoantibodies Against to Tumor-Associated Antigen Predict Clinical Outcome to Immune Checkpoint Inhibitor-Based Treatment in Advanced Non-Small Cell Lung Cancer

Expression of P16 in Non-Small Cell Lung Cancer and Its Prognostic Significance: a Meta-Analysis of Published Literatures.

Circulating IgG Antibody Against FOXP3 May Be a Potential Biomarker for Lung Cancer

Evaluation of serum autoantibodies against tumor-associated antigens as biomarkers in lung cancer

Circulating Antibodies to Linear Peptide Antigens Derived from ANXA1 and FOXP3 in Lung Cancer

Alteration of Circulating Natural Autoantibodies to CD25-derived Peptide Antigens and FOXP3 in Non-Small Cell Lung Cancer

Plasma Anti‐birc5 IgG May Be a Useful Marker for Evaluating the Prognosis of Nonsmall Cell Lung Cancer

Circulating Antibodies to Linear Peptide Antigens Derived from ANXA1 and FOXP3 in Lung Cancer.

Detection of p16 hypermethylation in circulating plasma DNA of non-small cell lung cancer patients.

Slag-3 in Non-Small-cell Lung Cancer Patients’ Serum

Does Selected Immunological Panel Possess the Value of Predicting the Prognosis of Early-Stage Resectable Non-Small Cell Lung Cancer?

Stem Signatures Associated Antibodies Yield Early Diagnosis and Precise Prognosis Predication of Patients with Non-Small Cell Lung Cancer

Circulating activated immune cells as a potential blood biomarkers of non-small cell lung cancer occurrence and progression

Anti-PD1/PDL1 IgG subclass distribution in ten cancer types and anti-PD1 IgG4 as biomarker for the long time survival in NSCLC with anti-PD1 therapy